Loading...
•
Jun 30, 2022
OPKO Health Q2 2022 Earnings Report
OPKO Health's financial performance declined due to lower COVID-19 testing volume and non-cash expenses related to a decrease in Sema4’s stock price.
Key Takeaways
OPKO Health reported a decrease in consolidated total revenues, driven by lower COVID-19 testing volume and a decrease in revenue from services. The company experienced an operating loss, and net loss was significantly impacted by a non-cash expense related to a decrease in Sema4's stock price.
Acquired ModeX Therapeutics, gaining proprietary immunotherapy technology and new executives.
Pfizer launched NGENLA® in Germany, Japan, and other global markets, resulting in $85 million in milestone payments to OPKO.
Completed the sale of GeneDx LLC to Sema4 Holdings Corp.
BioReference Laboratories' Scarlet Health® collaborated with Teladoc Health to offer in-home phlebotomy services.
Forward Guidance
The press release contains forward-looking statements regarding expected financial performance, market expectations, product sales, and the impact of acquisitions and partnerships. These statements are subject to various risks and uncertainties that could cause actual results to differ materially.
Positive Outlook
- Expected financial performance
- Market expectations
- Product sales
- Impact of acquisitions
- Partnerships
Challenges Ahead
- Down turns
- Changing regulatory landscape in the highly competitive healthcare industry
- Ability to get beneficial pricing approvals
- Manufacturing issues that may arise
- Patent positions and litigation
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...